Insights On CONTRACT PHARMA MANUFACTURING

31. Navigating The Highs And Lows Of Early Phase Clinical Trials 12/2/2025

    Convert uncertainty into opportunity by mastering scientific rigor, operational agility, and strategic foresight. Partnerships and proactive regulatory planning are essential for minimizing risk.

32. Time-To-Manufacture Reduced By 30% Through Rapid Transfer Strategy 12/2/2025

    Critical formulation deficiencies were solved through rapid batch manufacturing and process adjustments. This enabled a 30% reduction in time-to-manufacture and prevented delays to the start date.

33. How To Capture Growth In The Expanding Metabolic Drug Market 12/2/2025

    Driven by GLP-1 success and rising obesity rates, R&D investment in metabolic disease therapies now rivals oncology, demanding rapid development to overcome market challenges.

34. Resilience By Design: Lessons From Real-World Disruption 12/2/2025

    Resilience is the bridge to patient access. Discover how to design your logistics with intentional flexibility to withstand real-world disruptions and protect product integrity under pressure.

35. Why Supply Chain Integration Matters In Advanced Therapy Manufacturing 12/2/2025

    Fragmented supply chains increase risk and delay execution. Integration is key to establish a unified framework that enhances control, reduces administrative burden, and ensures program predictability.

36. Why Shipping System Qualification Matters In Advanced Therapies 12/2/2025

    Ensuring the integrity of advanced therapies requires documented evidence of robust shipping processes. Qualification is essential for compliance and maintaining continuity across the supply chain.

37. Built Or Bought? Why Biotechs Are Outsourcing Supply Chain Infrastructure 12/2/2025

    Scaling advanced therapies requires navigating extreme logistics and regulatory hurdles. Learn why moving to a flexible, outsourced model is essential for freeing capital and mitigating global risk.

38. Optimized Transient Transfection Platform: AAV Program From Gene To GMP 12/2/2025

    Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

39. Analytical Method Saves Dual-API Injectable Project From Stalling 12/2/2025

    Developing a stability-indicating analytical method for a dual-API injectable product requires careful forced degradation studies. Review the robust testing approach that ensured project progression.

40. Critical Path For Gene Therapy: AAV Analytical Lifecycle Considerations 12/2/2025

    Explore considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Review validation challenges and paths for maturation of analytics.